Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$8.69
-1.5%
$8.08
$3.76
$46.80
$53.42M2.77170,067 shs27,106 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.26
+0.2%
$0.31
$0.17
$0.42
$8.13M0.810,385 shs5,110 shs
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$1.53
$1.41
$0.85
$2.09
$40.12M0.5204,709 shs35,809 shs
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
$2.69
-2.0%
$2.40
$1.70
$20.00
$36.30M0.4113,475 shs27,737 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
+0.57%+18.71%-3.71%+56.66%-38.11%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
+0.19%-11.62%-15.32%-20.45%+31.25%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
+0.33%-0.33%+7.39%+15.53%-16.21%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-2.14%+37.00%+17.60%+21.78%+273,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.4194 of 5 stars
3.54.00.04.82.41.70.6
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/AN/AN/AN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
1.8144 of 5 stars
3.05.00.00.01.50.00.0
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
3.4203 of 5 stars
3.60.00.00.02.73.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
3.00
Buy$50.00475.71% Upside
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
2.00
Hold$2.6976.07% Upside
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
3.14
Buy$32.331,104.22% Upside

Current Analyst Ratings Breakdown

Latest INBP, LVTX, ALGS, and OKUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00
8/13/2025
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/5/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.24
8/5/2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$3.00 ➝ $1.50
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
$3.17M16.83N/AN/A$16.56 per share0.52
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$50.32M0.16$0.04 per share5.92$0.64 per share0.41
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
$4.99M8.04N/AN/A$0.76 per share2.01
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/A$5.79 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$131.21M-$19.79N/AN/AN/A-2,337.24%-22.41%-12.09%11/5/2025 (Estimated)
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$110K$0.046.56N/A2.37%6.36%4.84%9/18/2025 (Estimated)
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%N/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)

Latest INBP, LVTX, ALGS, and OKUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
-$0.28-$0.32-$0.04-$0.32N/AN/A
8/12/2025Q2 2025
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
-$1.23-$1.14+$0.09-$1.14N/AN/A
8/6/2025Q2 2025
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
-$2.35-$1.53+$0.82-$1.53$0.43 million$0.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/AN/AN/AN/AN/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
N/A
6.31
6.31
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.72
1.70
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
10.78
10.78
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/A
11.13
11.13

Institutional Ownership

CompanyInstitutional Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
60.43%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
N/A
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
90.98%

Insider Ownership

CompanyInsider Ownership
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
4.80%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.20%
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
9.50%
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
17.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aligos Therapeutics, Inc. stock logo
ALGS
Aligos Therapeutics
906.15 million5.86 millionNo Data
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15030.98 million10.16 millionNot Optionable
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
6026.31 million23.81 millionOptionable
OnKure Therapeutics, Inc. stock logo
OKUR
OnKure Therapeutics
N/A13.51 million11.09 millionN/A

Recent News About These Companies

Leerink Partnrs Has Positive Forecast for OKUR Q3 Earnings
OKUR OnKure Therapeutics, Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aligos Therapeutics stock logo

Aligos Therapeutics NASDAQ:ALGS

$8.68 -0.14 (-1.53%)
As of 02:32 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.26 +0.00 (+0.19%)
As of 08/19/2025 01:13 PM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

LAVA Therapeutics stock logo

LAVA Therapeutics NASDAQ:LVTX

$1.52 0.00 (0.00%)
As of 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

OnKure Therapeutics stock logo

OnKure Therapeutics NASDAQ:OKUR

$2.68 -0.06 (-2.01%)
As of 02:45 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.